Provision of genetic testing to the relatives of patients with hypertrophic cardiomyopathy (HCM) caused by pathogenic/likely pathogenic (P/LP) variants in sarcomere protein (SP) genes is standard of care in clinical practice guidelines (1). Here, TFF2 is linked to hypertrophic cardiomyopathy.